Details

Autor(en) / Beteiligte

• Miyamoto, Ippei
• Shimizu, Tetsuo
• Kusahana, Ryo
• Nomoto, Masayuki
• Fujiwara, Daishi
• Nishizawa, Tsukasa
• Hayashi, Kentaro
• Nakagawa, Yoshiko
• Gon, Yasuhiro

Titel

Anti-synthetase syndrome-associated interstitial lung disease possibly caused by atezolizumab in a patient with lung adenocarcinoma: a case report

Ist Teil von

• BMC pulmonary medicine, 2023-05, Vol.23 (1), p.159-159, Article 159

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Anti-aminoacyl-tRNA synthetase (ARS) antibody-positive patients present with a variety of symptoms, including interstitial lung disease (ILD), which is termed anti-synthetase syndrome (ASS). But it is rare that ASS-ILD is considered an immune-related adverse event after the use of immune checkpoint inhibitors (ICIs). A 47-year-old male with advanced lung adenocarcinoma was treated with platinum and ICI combination immunotherapy and was followed up as an outpatient. Nine months after the start of treatment, he developed a fever and cough, and imaging findings showed lung consolidations in the bilateral lower lung fields. The patient was positive for anti- ARS antibodies and was considered to have developed ASS-ILD due to ICIs remitted with steroid therapy. The patient was found to be positive for anti-ARS antibodies before ICI administration, and the antibody titer was elevated compared to that before ICI administration. The examination of anti-ARS antibodies pior to the administration of ICIs may be useful in predicting the development of ASS-ILD.